Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.Spiegel Jr., P.C., Jacquemin, M., Saint-Remy, J.M., Stoddard, B.L., Pratt, K.P.
(2001) Blood 98: 13-19
- PubMed: 11418455
- PubMed Abstract:
- Structure of the C2 domain of human factor VIII at 1.5 A resolution
Pratt, K.P.,Shen, B.W.,Takeshima, K.,Davie, E.W.,Fujikawa, K.,Stoddard, B.L.
(1999) Nature 402: 439
- Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure
Liu, M.L.,Shen, B.W.,Nakaya, S.,Pratt, K.P.,Fujikawa, K.,Davie, E.W.,Stoddard, B.L.,Thompson, A.R.
(2000) Blood 96: 979
The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-d ...
The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-derived inhibitory immunoglobulin G4kappa antibody (BO2C11) produced by an immortalized memory B-lymphocyte cell line interferes with the binding of factor VIII to phospholipid surfaces and to von Willebrand factor. The structure of a Fab fragment derived from this antibody complexed with the factor VIII C2 domain was determined at 2.0 A resolution. The Fab interacts with solvent-exposed basic and hydrophobic side chains that form a membrane-association surface of factor VIII. This atomic resolution structure suggests a variety of amino acid substitutions in the C2 domain of factor VIII that might prevent the binding of anti-C2 inhibitor antibodies without significantly compromising the procoagulant functions of factor VIII.
Graduate Program in Biomolecular Structure and Design, University of Washington, and Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.